http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Je‑Oh Lim,Je‑Won Ko,Tae‑Yang Jung,Woong‑Il Kim,So‑Won Pak,In‑Sik Shin,Won‑Kee Yun,Hyoung‑Chin Kim,Jeong‑Doo Heo,Jong‑Choon Kim 대한독성 유전단백체 학회 2020 Molecular & cellular toxicology Vol.16 No.3
Background Silica dioxide nanoparticles (SiONPs) have been used for various medical applications, including therapeutics and imaging, and the use of SiONPs has increased gradually over the years. However, despite an increase in the use of SiONPs, not much is known about mechanism of action of SiONPs and their pulmonary toxicity. Objective The present study investigated the pulmonary toxicity of SiONPs and explored the underlying mechanism of action, primarily focusing on thioredoxin-interacting protein (TXNIP)/NOD-like receptor pyrin domain-containing 3 (NLRP3) in SiONPs-treated mice. We investigated the toxic effects of SiONPs in the lung of BALB/c mice administered 5, 10, and 20 mg/kg SiONPs for 3 days. Results Exposure to SiONPs markedly increased inflammatory cell counts, including those of neutrophils and macrophages, and levels of inflammatory mediators, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α in a dose-dependent manner in the bronchoalveolar lavage fluid. Moreover, the inflammation was verified upon histopathological analysis. In addition, exposure to SiONPs increased the expression of TXNIP in a dose-dependent manner and, in turn, upregulated NLRP3 inflammasome proteins, which subsequently induced IL-1β production. Conclusion Collectively, exposure to SiONPs induced inflammation in the lungs of mice, which resulted in the activation of IL-1β production via the TXNIP-NLRP3 axis. Our results provide useful information on the pulmonary toxicity induced by SiONPs and provide insights into the underlying mechanism of action.
Park, Je-Kyun,Suh, Kahp-Yang Royal Society of Chemistry 2011 Lab on a chip Vol.11 No.1
<P>Graphic Abstract</P><P>Shooting for another success like the microelectronics industry—Guest Editors Je-Kyun Park and Kahp-Yang Suh highlight the contribution of Korean research to micro and nanofluidics. <IMG SRC='http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=c0lc90085k'> </P>
Park, Chan-Je,Jeon, Kyung-A,Kwon, Ho-Beom 大韓齒科保存學會 2006 Restorative Dentistry & Endodontics Vol.31 No.3
본 연구의 목적은 근관내 약제로 사용되는 수산화칼슘의 제거방법이 근관충전 후 치근단 미세누출에 미치는 영향을 알아보기 위함이다. 70개의 발거된 단근치를 엔진구동형 ProFile로 근관형성한 후 수용성 수산화칼슘 제제를 1주일간 적용하고 두 군으로 나누어 각기 다른 방법으로 제거하였다. A군은 NaOCI로 근관세정만을 시행하였으며, B군은 근관형성 시 사용된 file보다 한 단계 큰 크기의 ProFile을 사용하여 근관을 재형성한 후 NaOCI로 세척하였다. 근관충전 후 전기화학적 방법으로 24일 동안 치근단 누출을 측정, 비교하였다. 본 연구의 결과 수산화 칼슘 제거를 위한 두가지 방법은 근관충전후 치근단 미세누출에 있어서 차이가 없음을 알 수 있었다. This study evaluated the effect of two different calcium hydroxide (Ca(OH)_(2)) paste removal techniques on the apical leakage of canals obturated with gutta percha cones and sealer after removing a Ca(OH)_(2) dressing using an electrochemical method. Seventy extracted single-rooted teeth were instrumented on with Profile rotary files under NaOCI irrigation. Fifty-eight canals were filled with calcium hydroxide paste, which was then removed using one of the following two techniques. In group A, calcium hydroxide was removed using only NaOCI irrigation, and in group B, the canals were re-prepared with a Profile rotary files-one size larger than the previous instrument and were irrigated with NaOCI. In both groups, the root surfaces were coated twice with nail varnish from CEJ to an area 4㎜ away from the apex after canal obturation. Apical leakage was measured using an electrochemical method for 24 days. All the specimens showed leakddffqage that increased markedly in the first three days. There was no significant difference between the two groups (p > 0.05). The effect of two calcium hydroxide paste removal techniques on the apical leakage was not different during a short period.
PEG 분해균주의 분리와 PEG film의 상용성에 관한 연구
이제혁,정성제,이준열,전억한 경희대학교 부설 식량자원개발연구소 1993 硏究論文集 Vol.14 No.-
PEG를 sole carbon과 energy source로서 이용하는 미생물을 자연계에서 분리하였고, PEG의 분자량이 높아질수록 그 분해 미생물의 수가 감소하는 것을 확인하였다. 또한, liquid culture로서 PEG농도를 감소시키는 미생물을 선별하였고, 분해율은 PEG 8000이 약 18.8%였으며 PEG 10000은 약 25.4%인 것으로 조사되었다. PEG film의 제조를 위해 EMAA 및 EAA와의 상용성을 적외선 분광(IR) 스펙트럼을 사용하여 조사한 결과, EMAA와 EAA의 카르보닐기와 PEG의 에테르기와의 강한 수소결합이 형성으로 blend film제조시 상용성이 있는 것으로 확인되었다. Several strains capable of degrading PEGs(Polyethylene Glycols)were isolated and investigated for their biodgradation ability of PEGs. Microorganisms screened for the biodegradation studies were those grown on the PEG used as a sole carbon and energy source. It was known that the number of microorganisms decreased when grown on the high molecular weight of PEG(e.g. 20,000). A liquid culture was carried out with such microorgaisms and resulted in the decrease in PEG concentration meaning that PEG was degraded in the reactor. The biodegradability was found to be about 18.8% for PEG-8000 and 25.4% for PEG-10000, respectively. For the manufacture of biodegradable PEG film, EMAA/PEG and EAA/PEG blending ability was investigated with IR spectrum and showed that it was possible to produce blending film.
다발성 골수종에서 저용량 thalidomide, cyclophosphamide, dexamethasone (TCD) 요법의 효과
류충헌,정재현,고정해,장제혁,박영진,최규남,박봉수,이상민,주영돈 인제대학교 2008 仁濟醫學 Vol.29 No.-
Background and Objectives : The immunomodulatory drug thalidomide can inhibit angiogenesis and induce apoptosis in experimental models. It can also induce marked and durable response in newly diagnosed myeloma patients. Thalidomide has been used at doses ranging from 200 to 800 mg with significant toxicity. No data are available on the impact of low-dose thalidomide, cyclophosphamide and dexamethasone as initial therapy for myeloma patients. Design and Methods : To address this issue, newly diagnosed myeloma patients were treated with 50 mg/day thalidomide continuously and cyclophosphamide 150 mg/m², days 1-4 and dexamethasone 20 mg/m², days 1-5 and day 15-19, every month. Between October 2005 and October 2006, 14 patients (median age 54.5 years) were treated with low-dose thalidomide, cyclophosphamide and dexamethasone. Results : After a minimum of two cycles of treatment, 5 patients (55.5%) showed a partial remission. After four cycles of treatment, 10 patients (83.3%) showed a partial remission (n=6) and complete remission (n=4). After a median follow-up of 15.4 months, 1 year overall survival rate was 82.0%. Thalidomide was well tolerated without serious toxic effects. Conclusions : The combination of low-dose thalidomide, cyclophosphamide and dexamethasone demonstrates favorable response rate and 1 year overall survival rate in newly diagnosed myeloma. Severe toxicities were not seen with this combination.